Peer-influenced content. Sources you trust. No registration required. This is HCN.

CheckRareSustained uMRD Demonstrated in Elderly CLL Patients Receiving Ibrutinib Plus Venetoclax

The GLOW study is a phase 3 clinical trial evaluating the efficacy and safety of ibrutinib plus venetoclax (I+V) in elderly or unfit CLL patients. Patients receiving I+V are compared to patients receiving chlorambucil plus obinutuzumab (C+O). Previously this study reported reduced risk of disease progression with I+V vs C+O. This update, presented at ASH 2021, looked at undetectable minimal residual disease (uMRD) – a surrogate for PFS. uMRD was significantly higher in both peripheral blood and bone marrow in the I+V group.

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form